Nevada Medicaid Covers Hydroxyprogesterone Caproate

Effective Jan. 1, 2011, the Centers for Medicare & Medicaid Services (CMS) removed all Active Pharmaceutical Ingredients (APIs) from the CMS rebate-eligible product listing. Due to this action, 17-hydroxyprogesterone caproate (17-P), injectable hydroxyprogesterone, used to reduce the risk of certain pre-term births, was no longer rebate-eligible and could not be reimbursed by Nevada Medicaid.

To sustain the availability of this drug for reducing pre-term births, as of Jan. 3, 2011, Nevada Medicaid will forego federal financial participation for 17-hydroxyprogesterone caproate and reimburse providers for this drug.

According to a Food and Drug Administration (FDA) statement, the FDA will not take enforcement action against pharmacies that compound 17-P based on a valid prescription for an individually identified patient, unless the compounded products are unsafe, of substandard quality, or are not being compounded in accordance with appropriate standards for compounding sterile products. The full FDA statement is online at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm249025.htm.

If it is found that any claims affected by these changes must be reprocessed, the claim adjudication will be reported on a future remittance advice.